Literature DB >> 25773153

GM-CSF production by CD4+ T cells in MS patients: regulation by regulatory T cells and vitamin D.

E Peelen1, A-H Muris1, J Damoiseaux2, S Knippenberg1, K Broens3, J Smolders4, J W Cohen Tervaert5, R Hupperts6, M Thewissen7.   

Abstract

BACKGROUND/
OBJECTIVE: Data from animal models of MS suggest that GM-CSF(+)CD4(+)T cells are pathogenic cells. Therefore, GM-CSF production by CD4(+)T cells of MS patients and their susceptibility to regulatory mechanisms were investigated.
METHODS: Intracellular flowcytometry was performed to determine the GM-CSF(+)CD4(+)T cell fraction in PBMC and CSF of MS patients and controls. The effect of regulatory T cells (Tregs) on GM-CSF production by CD4(+)T cells was studied in MS patients using a proliferation-suppression assay. Finally, GM-CSF(+)CD4(+)T cell fraction and GM-CSF protein levels in supernatant were assessed in anti-CD3-stimulated CD4(+)T cell cultures derived from healthy controls and MS patients, in the presence or absence of the active vitamin D metabolite calcitriol.
RESULTS: The GM-CSF(+)CD4(+)T cell fraction in the peripheral blood did not differ between controls and MS patients. This T cell population could also be detected in the CSF of both subjects with MS as well as subjects with another diagnosis. In the CSF, it comprised a significant fraction of the T cell population. Upon in vitro stimulation of PBMC with anti-CD3 antibody, no differences were observed in GM-CSF(+)CD4(+)T cell frequencies. GM-CSF secretion was susceptible to regulation by Treg and vitamin D. Suppression of GM-CSF secretion by vitamin D was reduced in MS patients.
CONCLUSIONS: Our study showed no elevation in GM-CSF(+)CD4(+)T cell fractions in MS patients compared to controls. Furthermore, GM-CSF secretion was prone to regulation by Treg and vitamin D, the latter being less effective in MS patients.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  GM-CSF; Multiple sclerosis; Regulatory T cell; T helper cell; Vitamin D

Mesh:

Substances:

Year:  2015        PMID: 25773153     DOI: 10.1016/j.jneuroim.2015.02.007

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  5 in total

Review 1.  Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications.

Authors:  Manon Galoppin; Saniya Kari; Sasha Soldati; Arindam Pal; Manon Rival; Britta Engelhardt; Anne Astier; Eric Thouvenot
Journal:  Brain Commun       Date:  2022-06-30

2.  Altered regulatory T-cell fractions and Helios expression in clinically isolated syndrome: clues to the development of multiple sclerosis.

Authors:  Anderson P Jones; Stephanie Trend; Scott N Byrne; Marzena J Fabis-Pedrini; Sian Geldenhuys; David Nolan; David R Booth; William M Carroll; Robyn M Lucas; Allan G Kermode; Prue H Hart
Journal:  Clin Transl Immunology       Date:  2017-05-26

Review 3.  Genomic Effects of the Vitamin D Receptor: Potentially the Link between Vitamin D, Immune Cells, and Multiple Sclerosis.

Authors:  Ming Lu; Bruce V Taylor; Heinrich Körner
Journal:  Front Immunol       Date:  2018-03-12       Impact factor: 7.561

Review 4.  Granulocyte-Macrophage Colony-Stimulating Factor as a Therapeutic Target in Multiple Sclerosis.

Authors:  Jehan Aram; Anna Francis; Radu Tanasescu; Cris S Constantinescu
Journal:  Neurol Ther       Date:  2018-12-01

5.  Vitamin D and IFN-β Modulate the Inflammatory Gene Expression Program of Primary Human T Lymphocytes.

Authors:  Niccolò Bianchi; Stefan Emming; Chiara Zecca; Silvia Monticelli
Journal:  Front Immunol       Date:  2020-12-04       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.